|
|
|
|
| Now available on demand! Choosing the right CDMO for antibody development is crucial. The wrong partner can lead to delays and quality issues, while the right one can streamline development and improve commercialization success. Join Outsourced Pharma's expert panel on CDMO selection for biologic drug developers, where experts will discuss qualification processes, partnership management, team and facility compatibility, and how to leverage your CDMO's strategic expertise. |
|
|
|
|
By Carl Accettura, Global Pharma Advisory | Facing growing pressure from industry and Congress, FDA extended its enforcement deadline yet again, which has important implications for manufacturers. |
|
|
|
By P. Seeboldt and P. Dao, Sanofi, and B. Herren, a-connect | The project established predictability during testing and release for the production of medicine to support clinical trials. |
|
|
|
By John Giantsidis, president, CyberActa, Inc. | Life sciences companies are focusing on smart manufacturing, digital supply chain, and leveraging AI/ML. A good cybersecurity incident response plan can make the difference between a cybersecurity incident versus crisis. |
|
|
|
|
|
|
|
